Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bonita Rup is active.

Publication


Featured researches published by Bonita Rup.


Cancer | 1994

Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas

Hideki Yoshikawa M.D.; Wolfgang J. Rettig; Joseph M. Lane; Kunio Takaoka; Edward Alderman; Bonita Rup; Vicki Rosen; John H. Healey; Andrew G. Huvos; Pilar Garin-Chesa

Background. Bone morphogenetic proteins (BMPs) are potent inducers of bone formation. Functional and immunohistochemical studies have identified BMPs in a subset of osteosarcomas. In the present study, the authors extend the analysis of BMP expression to other bone and soft tissue sarcomas.


Cancer | 1994

Expression of bone morphogenetic proteins in human osteosarcoma. Immunohistochemical detection with monoclonal antibody

Hideki Yoshikawa M.D.; Wolfgang J. Rettig; Kunio Takaoka; Edward Alderman; Bonita Rup; Vicki Rosen; M. John Wozney; Joseph M. Lane; Andrew G. Huvos; Pilar Garin-Chesa

Background. Bone morphogenetic proteins (BMP) induce ectopic bone formation in vivo and may play a role in normal bone development. In addition, bone morphogenetic activity, as measured in a bone‐forming assay in immunodeficient, athymic nu/nu mice, is present in a proportion of osteosarcomas; this activity, which may be mediated by BMP, is correlated with a poor prognosis.


Aaps Journal | 2007

Critical ligand binding reagent preparation/selection: when specificity depends on reagents.

Bonita Rup; Denise O'hara

Throughout the life cycle of biopharmaceutical products, bioanalytical support is provided using ligand binding assays to measure the drug product for pharmacokinetic, pharmacodynamic, and immunogenicity studies. The specificity and selectivity of these ligand binding assays are highly dependent on the ligand binding reagents. Thus the selection, characterization, and management processes for ligand binding reagents are crucial to successful assay development and application. This report describes process considerations for selection and characterization of ligand binding reagents that are integral parts of the different phases of assay development. Changes in expression, purification, modification, and storage of the ligand binding reagents may have a profound effect on the ligand binding assay performance. Thus long-term management of the critical ligand binding assay reagents is addressed including suggested characterization criteria that allow ligand binding reagents to be used in as consistent a manner as possible. Examples of challenges related to the selection, modification, and characterization of ligand binding reagents are included.


Blood | 2001

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

David A. Roth; Craig M. Kessler; K. John Pasi; Bonita Rup; Suzanne G. Courter; Karen L. Tubridy


Thrombosis and Haemostasis | 1995

Evaluation of Recombinant Human Factor IX: Pharmacokinetic Studies in the Rat and the Dog

James C. Keith; Thomas Ferranti; Bibhu Misra; Thomas Frederick; Bonita Rup; Kyle McCarthy; Robert Faulkner; Larry Bush; Robert G. Schaub


Blood | 2003

Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs

Karen E. Russell; Eva H. N. Olsen; Robin A. Raymer; Elizabeth P. Merricks; Dwight A. Bellinger; Marjorie S. Read; Bonita Rup; James C. Keith; Kyle McCarthy; Robert G. Schaub; Trimothy C. Nichols


Archive | 2000

Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins

Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel J. Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman


Archive | 1999

Humanized immunoglobulin reactive with B7 therewith

Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel J. Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman


Archive | 2000

Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith

Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman


Archive | 1999

Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith

Man Sung Co; Maximiliano Vasquez; Beatriz M. Carreno; Abbie Cheryl Celniker; Mary Collins; Samuel J. Goldman; Gary S. Gray; Andrea Knight; Denise O'hara; Bonita Rup; Geertruida M. Veldman

Collaboration


Dive into the Bonita Rup's collaboration.

Top Co-Authors

Avatar

Beatriz M. Carreno

Washington University in St. Louis

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Man Sung Co

Memorial Sloan Kettering Cancer Center

View shared research outputs
Top Co-Authors

Avatar

Dwight A. Bellinger

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Elizabeth P. Merricks

University of North Carolina at Chapel Hill

View shared research outputs
Top Co-Authors

Avatar

Andrew G. Huvos

Memorial Sloan Kettering Cancer Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge